New-onset Type 1 Diabetes after COVID-19 mRNA Vaccination

During the ongoing coronavirus disease 2019 (COVID-19) pandemic, it is critical to ensure the safety of COVID-19 vaccines. We herein report a 51-year-old Japanese woman who developed acute-onset type 1 diabetes with diabetic ketoacidosis six weeks after receiving the first dose of a COVID-19 messeng...

Descripción completa

Detalles Bibliográficos
Autores principales: Yano, Masahiro, Morioka, Tomoaki, Natsuki, Yuka, Sasaki, Keyaki, Kakutani, Yoshinori, Ochi, Akinobu, Yamazaki, Yuko, Shoji, Tetsuo, Emoto, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107966/
https://www.ncbi.nlm.nih.gov/pubmed/35135929
http://dx.doi.org/10.2169/internalmedicine.9004-21
Descripción
Sumario:During the ongoing coronavirus disease 2019 (COVID-19) pandemic, it is critical to ensure the safety of COVID-19 vaccines. We herein report a 51-year-old Japanese woman who developed acute-onset type 1 diabetes with diabetic ketoacidosis six weeks after receiving the first dose of a COVID-19 messenger ribonucleic acid (mRNA) vaccine. Laboratory tests indicated exhaustion of endogenous insulin secretion, a positive result for insulin autoantibody, and latent thyroid autoimmunity. Human leukocyte antigen typing was homozygous for DRB1*09:01-DQB1*03:03 haplotypes. This case suggests that COVID-19 vaccination can induce type 1 diabetes in some individuals with a genetic predisposition.

Ejemplares similares